More on Synthetic Biologics Q1 results


Shares of nano cap Synthetic Biologics (SYN +17.2%) jump on a 40% increase in volume in response to its Q1 financial report and business update.

Operating loss: ($3.8M) (-72.7%); cash & equiv: $11.2M (-23.2%).

The company will conduct a 28-day bridging toxicology study on its lead anti-infective product candidate, SYN-004 next month followed by an IND application. A Phase 1a/1b trial should begin in 2H 2014 with preliminary top-line results by year end. A Phase 2 trial will follow in 1H 2015.

A Phase 1 trial for its anti-pertussis product candidate, SYN-005, should begin in Q1 2015 with top-line data available after 90 days. A Phase 2 trial will follow with top-line results expected by 2H 2015. The company intends to request Orphan Drug Designation for SYN-005 for the treatment of pertussis (whooping cough).

Expect an additional capital raise in the near future.

Comments (2)
  • mazlat10
    , contributor
    Comments (211) | Send Message
     
    why don't you state also that they are also starting right away a test with ALL the drugs which work with M.S.???
    15 May 2014, 11:24 AM Reply Like
  • RHMASSING
    , contributor
    Comments (592) | Send Message
     
    Not only this news failed to report its MS drug Trimesta's discussion which was the first item brought by the CEP and also the last item mentioned at the end for its significance. The CEO particularly mentioned the confusion related to the PII data. On top of the he mentioned consistently in the cc that multiple partners (with deep pockets) are interested in the data and are deciding whar angle to approach the drug with the partnership. Surprising this news never even mentioned Trismeta at all, but added " expect capital raise in the near future". which was never even mentioned or questions asked! Put all these deliberate omission and addition to this "news" follow-up, the attempt to drive down the share price is simply too obvious. Wonder how SA would have allowed such biased report in print. However the share price still is up substantially in a terrible downward market.
    15 May 2014, 12:02 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs